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We analyzed the outcomes of 61 patients with hematologic malignancies who underwent double-unit cord
blood transplantation (dCBT) after myeloablative conditioning performed as part of a prospective multicenter
phase II study. The conditioning regimen for dCBT included total body irradiation, cyclophosphamide, and
granulocyte colony-stimulating factor combined with cytosine arabinoside for myeloid malignancies and
with total body irradiation and cyclophosphamide for lymphoid malignancies. The cumulative incidence of
neutrophil engraftment after dCBT was 85% (95% conﬁdence interval [CI], 73%-92%). All 51 of the patients who
engrafted had complete chimerism derived from a single donor by day þ60. Only the degree of HLA disparity
in the host-versus-graft direction had an impact on unit dominance. The cumulative incidence of grade II-IV
acute graft-versus-host disease was 25% (95% CI, 15%-37%), and that of chronic graft-versus-host disease was
32% (95% CI, 20%-44%). The 1-year cumulative incidence of relapse was 23% (95% CI, 13%-34%), and that of
transplantation-related mortality was 28% (95% CI, 17%-39%). With a median follow-up of 41 months, event-
free survival was 48% (90% CI, 37%-58%) at 1 year and 46% (90% CI, 35%-56%) at 3 years. Event-free survival at 3
years was 67% (95% CI, 46%-81%) for patients with standard risk and 29% (95% CI, 15%-45%) for those with
advanced risk. This study suggests that dCBT after myeloablative conditioning is a promising alternative for
adults and large children with hematologic malignancies who need stem cell transplantation but lack
a suitable adult donor or an adequate single-unit cord blood graft.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION malignancies and TBI, CY, and granulocyte colony-
Cord blood (CB) is being increasingly used as an alterna-
tive source of hematopoietic stem cells for adults with
hematologic malignancies requiring hematopoietic stem cell
transplantation (HSCT) [1-5]. Although CB has advantages,
including rapid availability [6] and low risk of severe acute
graft-versus-host disease (GVHD) despite HLA mismatches,
the low cell dose in a single CB unit contributes to high rates
of graft failure and transplantation-related mortality (TRM),
especially in adults and large children [7-9]. Double-unit CB
transplantation (dCBT) was introduced to overcome these
obstacles [10] and is becoming more widely applied [11-15].
We conducted a prospective multicenter Phase II study
assessing the safety and efﬁcacy of dCBT for patients with
high-risk hematologic malignancies. We used relatively
standard myeloablative conditioning regimens: total body
irradiation (TBI) plus cyclophosphamide (CY) for lymphoidedgments on page 818.
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13.02.011stimulating factor (G-CSF) combined with cytosine arabino-
side (ara-C) for myeloid malignancies. We used cyclosporine
A (CyA) and short-term methotrexate (MTX) for GVHD
prophylaxis.PATIENTS AND METHODS
Thirty-nine centers participated in this study after approval by each
pertinent Institutional Review Board (trial identiﬁer: UMIN: C000000359,
C-SHOT 0507). Written informed consent was obtained from all patients
before transplantation.Eligibility Criteria
Inclusion criteria were as follows: (1) age <55 years with a high-risk
hematologic malignancy; (2) no HLA-matched or single antigen-
mismatched related donor available; (3) no HLA-matched unrelated donor
available, or requiring urgent transplantation even if an HLA-matched
unrelated donor were available; (4) no 4-6/6 HLA-A, -B, or -DR serologi-
cally antigen-matched single CB unit containing a cell dose >2.5  107/kg;
(5) no previous stem cell transplantation; (6) no active infection at the start
of conditioning chemoradiotherapy; and (7) HIV-negative status. Patients
with an Eastern Cooperative Oncology Group performance status 2, ejec-
tion fraction <50%, SaO2 (arterial oxygen saturation) <93% in room air,
serum creatinine of 1.3 mg/dL, total bilirubin 1.6 mg/dL, or glutamic-
oxaloacetic transaminase 2 times the normal value were excluded.
Patients with Down syndrome or Fanconi anemia were also excluded.Transplantation.
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CB units were obtained fromCB banks belonging to the Japan Cord Blood
Bank Network. The criterion for CB unit selection was 4-6/6 HLA-A, -B, and
-DR antigens matched to the recipient. One of the 2 units should contain
a cell dose of at least 1.5  107/kg. The total cell dose of the 2 units had to be
>2.5 107/kg, and transplantation of 2 units each with a cell dose >2  107/
kg was not allowed.
Treatment
All patients received a myeloablative preparative conditioning regimen
of 12 Gy TBI fractionated in 4 or 6 doses. Ara-C was given at a dose of 3 g/m2
every 12 hours for 2 days (days -5 and -4). Recombinant human G-CSF was
given by continuous infusion at a dose of 5 mg/kg/day; infusion was started
at 12 hours before the ﬁrst dose of ara-C and stopped at the completion of
the last dose. CY was administered i.v. at 60 mg/kg/day for 2 days (days -3
and -2). A regimen of TBI, CY, and G-CSF combined with ara-C was used for
patients with myeloid leukemias and myelodysplastic syndrome (MDS) [1].
TBI plus CY was used for those with lymphoid malignancies. At 2 days after
completion of conditioning, CB units were thawed and then infused
sequentially in an arbitrary order and nonmandatory time interval after
premedication with hydrocortisone (100 mg) and hydroxyzine hydrochlo-
ride (25 mg).
GVHD prophylaxis was provided with CyA plus short-term MTX. CyA
was given by continuous infusion at a dose of 3 mg/kg/day starting on day -1.
MTX was given at 15 mg/m2 i.v. on day þ1 and at 10 mg/m2 on days þ3
and þ6. Once oral intake could be tolerated, oral CyA was started at a dose
ratio of 1:2.5 in 2 divided doses per day based on the last i.v. dose. In the
absence of GVHD after day þ60, CyA was tapered by 10% to 20% per week
until it could be discontinued. The supportive care regimen, including
prophylaxis for infection, was similar to that for single-unit CBT in each
transplantation center. All patients received G-CSF starting on day 5 and
continuing until the absolute neutrophil count (ANC) reached 5000/mL.
HLA Typing and Chimerism Analysis
HLA typing of the recipient and CB unit was determined by low-
resolution (2 digits) and/or high-resolution (4 digits) DNA typing for HLA-
A, -B, -C, and -DRB1. Donor chimerism was determined serially for bone
marrow and/or blood at days þ14, þ30, þ60, and þ100 after dCBT, and at
additional time points as needed. The analytic method used was based on
the quantitative ampliﬁcation of informative polymorphic short tandem
repeat regions in the recipient and the donor.
Deﬁnitions
Patients who underwent dCBT in ﬁrst or second remission of acute
myelogenous leukemia (AML), in ﬁrst remission of acute lymphoblastic
leukemia (ALL) and malignant lymphoma (ML), or in the chronic phase of
chronic myelogenous leukemia (CML) and refractory anemia of MDS were
classiﬁed as standard risk. All others were classiﬁed as advanced risk.
Neutrophil recovery was deﬁned as achievement of an absolute
neutrophil count (ANC) of 500/mL for 3 consecutive days; platelet recovery
was deﬁned as a count of 50,000/mL without transfusion support. Primary
engraftment failure was deﬁned as the absence of donor-derived myeloid
cells on the day of death or day þ60 in patients surviving beyond day þ2þ8
after dCBT, or when a second stem cell transplantation was required for
donor-derived myeloid recovery. Diagnosis and clinical grading of acute
GVHD (aGVHD) were performed according to established criteria [16].
Relapse was deﬁned as recurrence of the underlying hematologic malig-
nancy. TRM was deﬁned as death during a continuous remission. Disease-
free survival (DFS) was deﬁned as survival in a state of continuous
remission. Event-free survival (EFS) was deﬁned as survival in a state of
remission without engraftment failure.
Statistical Analyses
The primary endpoint of this studywas 1-year EFS; secondary endpoints
were neutrophil and platelet engraftment, incidence of aGVHD and chronic
GVHD (cGVHD), toxicity within 28 days, incidence of TRM and relapse, DFS,
and overall survival (OS). The expected and threshold EFS at 1 year were
estimated as 60% and 40%, respectively. With a statistical power of 90% and
a 1-sided type I error of 5%, the number of eligible patients required for this
study was calculated as 56 using a binomial analysis method. The projected
sample size was 70 patients, assuming that 20% of patients would be inel-
igible. Primary endpoint analysis was performed using the Kaplan-Meier
method to calculate the probability of EFS. Treatment was considered
effective if the lower limit of the 90% conﬁdence interval (CI) exceeded the
threshold EFS (ie, 40%).
Cumulative incidence curves were used in a competing-risks setting to
calculate the probabilities of neutrophil and platelet recovery, aGVHD,
cGVHD, relapse, and TRM. For neutrophil and platelet recovery, death beforerecovery was the competing event; for GVHD, death without GVHD and
relapse was the competing events; for relapse, death without evidence of
relapse was the competing event; and for TRM, relapse was the competing
event. OS, DFS, and EFS were calculated by the Kaplan-Meier method. The
log-rank test was used for univariate comparisons. For multivariate analysis
of prognostic variables affecting transplant outcomes, a Fine-Gray model
was used to analyze transplantation outcomes with competing risks. A Cox
proportional hazard regression model was used to analyze other outcomes.
The following variables were considered: recipient cytomegalovirus (CMV)
serology (positive versus negative), recipient age at enrollment (age 40
years versus <40 years; cutoff point was around the median), degree of ABO
matching between recipient and engrafting unit (major mismatch versus
matched or minor mismatch), sex matching between recipient and
engrafting unit (mismatched versus matched), degree of HLA matching
between donor and recipients (2 antigen- mismatched versus 0 or 1
antigen-mismatched, with HLA matching deﬁned by the worst-matched of
the 2 units), disease status at transplantation (advanced versus standard),
cryopreserved TNC dose (median, <3.52  107/kg versus 3.52  107/kg),
CD34þ cell dose (median,<1.04/kg 105/kg versus1.04105/kg), and cell
dose difference [(TNC of large unit  TNC of smaller unit)/(TNC of large unit,
15% versus <15%)], and degree of HLA mismatch between the 2 units (3
antigen mismatches versus 2 antigen mismatches).
Variables found to affect outcome with a P value <.20 on univariate
analyses were selected for themultivariate analyses. Variables were selected
in a backward stepwise manner with a variable retention criterion of P< .05
for the ﬁnal model. The Wilcoxon signed-rank test was used to evaluate the
effect of cell dose and HLA compatibility on engraftment of a predominant
single CB unit, and the McNemar test was used for evaluation of categorical
factors. The median duration of follow-up of survivors was 41 months
(range, 12 to 57.4 months). Results are reported as of March 2011. Calcula-
tions were performed using Stat View J version 5.0 and Stata version 11.1
(StataCorp, College Station, TX).RESULTS
Patient and Graft Characteristics
A total of 70 patients were enrolled between April 2006
and January 2010. Nine patients did not undergo dCBT, 7
because of disease progression and 2 because they received
a graft from another source. Patient and graft characteristics
are summarized in Table 1. The 61 patients who underwent
dCBT included 8 females and 53 males, with a median age of
37 years (range, 10 to 54 years) and a median body weight of
70.5 kg (range, 50.1 to 129.8 kg). Antibodies against CMV
were detected in 75.4% of the patients; CMV antibody was
not tested in 3 patients. The underlyingmalignancy was AML
in 30 patients, ALL in 17 patients, CML in 6 patients, MDS in 5
patients, and ML in 3 patients. Disease status at dCBT was
classiﬁed as standard risk in 27 patients and as advanced risk
in 34 patients. The median TNC and CD34þ cell doses (both
units combined) at cryopreservation were 3.52  107/kg
(range, 2.25 to 4.43  107/kg) and 1.04  105/kg (range, 0.39
to 2.67  105/kg), respectively. The median TNC doses of the
larger and smaller units were 1.90  107/kg (range, 1.47 to
2.48  107/kg) and 1.60  107/kg (range, 0.74 to 1.97  107/
kg), respectively. In 1 patient, the TNC dose of the larger unit
was decreased from >1.5  107/kg at registration to 1.47 
107/kg at dCBT because of weight gain. Because 1.47 rounded
off to 1 decimal place is 1.5, we decided to include this case in
the analyses.
HLA matching for HLA-A, -B, and -DRB1 low- and high-
resolution types between recipients and donors and
between donors is described in Table 1. When the graft with
fewest HLA mismatches was counted for each recipient, only
2 patients (3%) received a graft that contained at least 1 unit
in which HLA-A, -B, and -DRB1 were matched at a low-
resolution level to the recipient; 21 patients (34%) received
a graft with at least 1 unit 5/6 HLA-matched to the recipient;
and 38 patients (62%) received a graft with both units 4/6
HLA-matched to the recipient. Among the 58 patients with
HLA-DRB1 typed by high-resolution DNA typing, 2 patients
Table 1
Patient and Graft Characteristics
Characteristic Value
Number of patients 61
Sex, male/female, n 53/8
Age, years, median (range) 37 (10-54)
Body weight, kg, median
(range)
70.5 (50.1-129.8)
Diagnosis and disease status
at CBT, n
ALL 17 (CR1, 8; CR2, 6; relapse, 3)
AML 30 (CR1, 6; CR2, 11; CR3, 1; relapse,
6; PIF, 4; no induction therapy, 2)
CML 6 (AP, 1; BC, 5)
MDS 5 (RA, 2; RAEB2, 3)
Non-Hodgkin lymphoma 3 (refractory, 3)
CMV antibody, positive/
negative/unknown, n
46/12/3
Performance status, 0/1, n 48/13
Cell dose at cryopreservation,
median (range)
TNC, 107/kg
Total 3.52 (2.25-4.43)
Large unit 1.90 (1.47-2.48)
Small unit 1.60 (0.74-1.97)
CD34þ cells, 105/kg
Total 1.04 (0.39-2.67)
Large unit 0.50 (0.12-2.41)
Small unit 0.46 (0.02-1.42)
GM-CFU, 103/kg
Total 27.42 (0.42-100.9)
Large unit 11.94 (0.17-39.6)
Small unit 12.85 (0.25-88.98)
ABO compatibility, large
unit/small unit, n
Major mismatches 23/20
Minor mismatches 16/16
Matches 22/25
HLA compatibility, n
-A, -B, and -DRB1
low resolution
5/6 þ 6/6 1
5/6 þ 5/6 6
4/6 þ 6/6 1
4/6 þ 5/6 15
4/6 þ 4/6 38
-A and -B low resolution,
-DRB1 high resolution
5/6 þ 5/6 3
4/6 þ 6/6 1
4/6 þ 5/6 10
4/6 þ 4/6 17
3/6 þ 6/6 1
3/6 þ 5/6 4
3/6 þ 4/6 13
3/6 þ 3/6 4
2/6 þ 4/6 1
2/6 þ 3/6 4
HLA compatibility to each
unit, n
-A, -B, and -DRB1 low
resolution
6/6 1
5/6 14
4/6 13
3/6 23
2/6 10
-A and -B low resolution,
-DRB1 high resolution
6/6 0
5/6 8
4/6 12
3/6 20
2/6 15
1/6 6
AP indicates accelerated phase; BC, blast crisis; CR, complete remission; PIF,
primary induction failure; RA, refractory anemia; RAEB, refractory anemia
with excess blasts.
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matched unit, 17 (29%) received at least one 5/6 HLA-
matched unit, 31 (53%) received at least one 4/6
HLA-matched unit, 8 (14%) received at least one 3/6 HLA-
matched unit. Three, 17, and 4 patients received a graft
with both units 5/6, 4/6, and 3/6 HLA-matched to the
recipient, respectively. The units were 6/6 HLA-Ae, -Be, and
DRB1ematched at low resolution to each another in
1 patient, 5/6 matched in 14 patients, 4/6 matched in
13 patients, 3/6 matched in 23 patients, and 2/6 matched in
10 patients. When HLA was typed by HLA-A and -B low-
resolution and -DRB1 high-resolution typing, the units
were 5/6 matched to each other in 8 patients, 4/6 matched
in 12 patients, 3/6 matched in 20 patient, 2/6 matched in
15 patients, and 1/6 matched in 6 patients.
Survival
The median follow-up for survivors (n ¼ 32) was 41
months. EFS at 1 year was 48% (90% CI, 37%-58%) (Figure 1A).
One-year EFS at 1 year was 67% (95% CI, 46%-81%) in patients
with standard risk and 32% (95% CI,18%-48%) in patients with
advanced risk at dCBT, and 3-year EFS was 67% (95% CI, 46%-
81%) in patients with standard risk and 29% (95% CI,15%-45%)
in those with advanced risk (P ¼ .023) (Figure 1B). One-year
DFS was 49% (95% CI, 36%-61%), and 1-year OS was 57% (95%
CI, 44%-69%). Three-year DFS was 47% (95% CI, 34%-59%), and
3-year OS was 54% (95% CI, 40%-65%). Disease status at
transplantation was the sole prognostic factor affecting EFS
(relative risk [RR], 2.71; P ¼ .011). No other variable consid-
ered had a signiﬁcant effect on EFS.
Toxicity Within 28 Days after dCBT
Toxicities occurring within 28 days after dCBT were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3. The most
frequent grade 3-4 toxicity was infection, occurring in 43 of
61 patients (70.5%); other grade 3-4 toxicities included
nausea/vomiting (17 patients; 27.9%), oral mucosa lesions
(16; 26.2%), diarrhea (13; 21.3%), cardiac events (6; 9.8%),
liver toxicity (6; 9.8%), bleeding (5; 8.2%), neurologic events
(3; 4.9%), renal/urinary events (3; 4.9%), skin toxicity (3;
4.9%), lung toxicity (2; 3.3%), and thrombotic thrombocyto-
penic purpura/hemolytic uremic syndrome (1; 1.6%). Grade 4
toxicities involving infections were seen in 5 patients (8.2%),
and those involving the heart occurred in 2 patients (3.3%).
Other grade 4 toxicities included bleeding and neurologic,
lung, and liver toxicities, which were seen in 1 patient each.
Hematopoietic Recovery and Chimerism
The cumulative incidence of neutrophil recovery was 67%
(95% CI, 53%-77%) at day þ28 and 85% (95% CI, 73%-92%) at
day þ50 (Figure 2). The cumulative incidence of platelet
recovery at dayþ180 was 77% (95% CI, 66%-89%). Themedian
time to neutrophil recovery was 25 days (range, 17 to 49
days). A greater degree of HLA matching between the 2 units
(3 antigen mismatches with increased risk of no neutrophil
recovery compared with 2 antigen mismatches; RR, 0.53;
P ¼ .023) was the sole risk factor affecting neutrophil
recovery.
Three patients (5%) died too early to allow evaluation of
engraftment (2 patients on day þ7 and 1 patient on
day þ12). Failure of primary engraftment occurred in 7
patients; 6 of these 7 patients underwent a second trans-
plantation (single-unit CBT in 3, autologous peripheral blood
stem cell transplantation in 2, haploidentical peripheral
Figure 1. Kaplan-Meier analysis of EFS in patients with dCBT after myeloablative conditioning (A) and according to disease status (B). Patients with standard risk had
signiﬁcantly better posttransplantation survival than those with advanced risk (P ¼ .023, log-rank test).
Figure 2. Cumulative incidence of neutrophil engraftment after myeloablative
conditioning and subsequent dCBT.
S. Kai et al. / Biol Blood Marrow Transplant 19 (2013) 812e819 815blood stem cell transplantation in 1) between day þ27 and
day þ49. Only 1 of these patients survived beyond 1 year
after dCBT.
All but 1 of the 51 patients with donor engraftment had
complete chimerism derived from a single donor (median,
100%; range, 91.2% to 100%) by day 30 after dCBT. One patient
demonstrated mixed chimerism from both donors (81.6%
and 11.5%) at day þ30, but this changed to complete
chimerism of single-donor origin by day þ60.
Predicting Factors Responsible for Unit Dominance
The degree of HLA disparity in the host-versus-graft
(HVG) direction was associated with unit dominance
(Table 2). Twenty of the 51 patients with donor engraftment
received 2 units with varying degrees of HLA disparity (HLA-
A, -B, and -DR antigen-level typing). Of these, the unit that
was better HLA-matched to the recipient engrafted in 15
patients, whereas the more poorly matched unit predomi-
nated in 5 patients (P¼ .0218). Twenty-seven of 49 engrafted
patients typed by HLA-A or -B antigen-level and -DRB1 high-
resolution typing received 2 units with different degrees of
HLA disparity; of these, the better-matched unit engrafted in
21 patients (P ¼ .0056).
There was no correlation between unit dominance and
cell dose (cryopreserved TNCs, P ¼ .4589; cryopreserved
CD34þ cells, P ¼ .3823; cryopreserved granulocyte macro-
phage colony-forming units (GM-CFU), P ¼ .6854; infused
TNCs, P ¼ .6114; infused CD34þ cells, P ¼ .3875; infused
GM-CFU, P ¼ .8405). Other factors, including sex match (P ¼
.7003), ABOmatch (P¼ 1.0), order of infusion (P¼ .4838), and
graft viability (P ¼ .6152), were not associated with unit
dominance.
GVHD
aGVHD developed in 33 of the 61 patients (54%), classiﬁed
as grade I in 18 patients, grade II in 11, grade III in 3, and grade
IV in 1 (25% grade II-IV and 7% grade III-IV). cGVHD was
observed in 18 of the 50 evaluable patients who survived for
>100 days, and was extensive in 9 patients. The cumulative
incidence of grade II-IV aGVHD was 25% (95% CI, 15%-37%),
and that of cGVHD at 1 year was 32% (95% CI, 20%-44%)
(Figure 3A and B). No risk factors for the development of
grade II-IV aGVHD were identiﬁed in univariate and multi-
variate analyses including HLA disparities (P ¼ .327).
Relapse
Relapse occurred in 15 patients, between 57 and 573 days
(median, 135 days) after dCBT. The cumulative incidence of
relapse at 1 year was 23% (95% CI, 13%-34%) (Figure 3C).Seven of 17 patients with ALL relapsed, comparedwith only 8
of 41 patients withmyeloid malignancies (AML, 6 of 29; CML,
1 of 6; MDS, 1 of 6). In terms of disease status at trans-
plantation, relapse occurred in 4 of 27 patients with standard
risk and in 11 of 34 patients with advanced risk. No risk
factors for relapse were identiﬁed by univariate and multi-
variate analyses, including disease status at CBT (P ¼ .291)
and HLA disparities (P ¼ .156).TRM and Cause of Death
The cumulative incidence of TRM was 15% (95% CI, 7%-
25%) at day þ100 and 28% (95% CI, 17%-39%) at 1 year
(Figure 3D). No risk factors for TRM were identiﬁed on
univariate and multivariate analyses. The causes of death are
listed in Table 3. Disease progressionwas the leading cause of
death. Of the 29 patients who died between 7 and 1368 days
(median,188 days) after dCBT,15 died from causes other than
relapse: graft failure in 5 (of whom 3 died from infection and
1 died from hepatic veno-occlusive disease after a second
transplantation), infection without graft failure in 2, organ
failure in 3, acute respiratory distress syndrome/interstitial
pneumonia in 3, and cGVHD and bleeding in 1.DISCUSSION
The present study is the ﬁrst reported analysis of dCBT in
Japan. In this multicenter Phase II study, greater HLA
disparities between recipient and donor and between each of
the 2 units were found compared with those reported in
previous studies of dCBT, becausewe selected the 4-6/6 HLA-
Table 2
Degree of HLA Disparity in the HVG Direction and Unit Dominance
Number of HLA
Mismatches in
the HVG Direction
for Winner/Loser
Difference
in HLA
Mismatches
Number of Patients with Sustained
Engraftment
HLA-A, -B,
and -DR at
Low Resolution
Level
HLA-A and -B at
Low Resolution
Level, HLA-DRB1
at High Resolution
Level
1/1 0 11 3
2/2 20 15
3/3 0 4
0/1 1 1 1
1/2 13 7
2/3 0 6
3/4 0 1
0/2 2 1 1
1/3 0 4
2/4 0 1
1/0 1 1 0
2/1 4 2
3/2 0 2
4/3 0 1
3/0 3 0 1
P ¼ .0218 P ¼ .0056
Analyses were performed with the Wilcoxon signed-rank test.
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resolution DNA typing level of HLA-A, -B, and -DRB1, with
no consideration of uniteunit match. The lower limit of the
90% CI did not exceed the threshold EFS by 3% in primary
endpoint analyses. The threshold and expected EFS was
estimated prior to study initiation according to survival
results of single-unit CBT (EFS of 40% at 1 year; unpublished
data, Japan Cord Blood Bank Network, 2005) and dCBT [17]
(EFS of 64% at 1 year) for adults. In these studies, 21% and
36% of patients were received CBT in advanced-risk disease
status, respectively, whereas 54% of patients in this study
were in advanced-risk disease status at the time of dCBT. Our
survival data are comparable to earlier reports of dCBT afterFigure 3. Cumulative incidence of grade II-IV aGVHmyeloablative conditioning [10-15]; thus, we can conﬁrm
that dCBT after myeloablative conditioning is a promising
alternative option for adults and large children with hema-
tologic malignancies who need HSCT but do not have a suit-
able related/unrelated donor or an adequate single-unit CB
graft. We have also shown that HLA disparity in the HVG
direction helps determine which unit was engrafted. These
data may provide clinically useful information to aid in the
selection of CB units for dCBT.
Our cumulative incidence of neutrophil engraftment of
85% and median time to neutrophil recovery of 25 days are
comparable to previously reported values for dCBT with
myeloablative conditioning (ie, cumulative incidence of
neutrophil engraftment, 80%-94%; median time to neutro-
phil recovery, 23-25 days) [10,12-15]. The degree of HLA
disparity between the 2 units was the sole factor associated
with neutrophil engraftment. On the other hand, uniteunit
HLA match reportedly had no signiﬁcant effect on sus-
tained engraftment and speed of neutrophil recovery [18].
Further studies are needed to investigate the inﬂuence of
cross-immunologic reactions between the 2 units on
neutrophil engraftment.
Our results are in agreement with previously reported
data, which indicated that 1 CB unit becomes predominant
and supports sustained hematopoiesis in dCBT. The param-
eters that determine unit dominance have not yet been
elucidated. In our analysis, only the degree of HLA disparity
in the HVG direction was correlated with unit dominance. To
our knowledge, this is the ﬁrst report suggesting that host-
versus-graft immune reactions play a role in determining
the engrafting unit. There was no correlation between
dominance and the doses of TNCs, CD34þ cells, and GM-CFU
or ABO, sex mismatch, cell viability, or order of infusion.
Previous reports have implied that CD3þ, GM-CFU, and
CD34þ cell doses and the viability of CD34þ cells were
associated with the unit dominance [14,18-21], and that the
presence of graft-versus-graft reactions mediated by CD8þ
T cells expanding from the dominant unit play a critical roleD (A), cGVHD (B), relapse (C), and TRM (D).
Table 3
Primary Causes of Death after dCBT
Cause of Death Number of
Patients
Time of Death after dCBT (Day of Death)
<100 Days 100-365 Days >365 Days
Relapse/disease progression 14 1 (day 12) 10 (days 134, 151, 197, 207*,
211, 225, 250y, 254, 266, and 296)
3 (days 419, 672,
and 1368)
Graft failure 5 5 (days 28, 32z, 53z, 74x, and 90z)
Infection without graft failure 2 2 (days 132 and 183)
Organ failure 3 1 (day 7) 2 (days 272 and 289)
cGVHD 1 1 (day 239)
Bleeding 1 1 (day 7)
ARDS/IP 3 1 (day 82) 2 (days 118 and 188
ARDS indicates acute respiratory distress syndrome; IP, interstitial pneumonia.
* Death by suicide after relapse on day þ57.
y Death by relapse after second transplantation for graft failure.
z Death by infection after second transplantation.
x Death by hepatic veno-occlusive disease after second transplantation.
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importance of CD3þ cell count and CD34þ cell viability
because we did not assay these parameters in our study.
Furthermore, there are reports concerning the effect of pre-
formed donor-speciﬁc anti-HLA antibodies on graft failure or
unit loss in dCBT [23]. Whether the unit dominance is
inﬂuenced by immune reactions between the units or
between the recipient and the units still remains to be
determined. On the other hand, the use of 2 units might
simply give the recipient a better chance of having a unit
with a sufﬁciently high potential for engrafting. Further
study is warranted.
In single-unit CBT, the doses of TNCs and CD34þ cells at
cryopreservation or at infusion have important effects on
survival [7-9]. According to a recent report by Sanz et al. [24],
in adults with AML, a low dose of TNCs (<2  107/kg) at
infusionwas the only signiﬁcant factor associated with lower
leukemia-free survival (LFS at 4 years; <2.0107/kg versus
2.0 107/kg, 25% versus 75%) [24]. Based on the foregoing
results, the suggested dose of TNC at cryopreservation should
not be <2.5  107/kg, given the anticipated cell loss of
approximately 20% [25,26]. In this study, the TNC dose in the
large unit was <2.5107/kg in all recipients and further that
was <2.0107/kg in 38 patients (62%). Because dCBT was
performed, these patients had a chance to undergo stem cell
transplantation and achieved an EFS of 46% at 3 years, which
is similar to or better than the survival seen with single-unit
CBT [24,27]. The extent of the beneﬁt has not been demon-
strated by a matched-cohort analysis or prospective
randomized trial, however.
The reported incidence of grade II-IV aGVHD is higher in
patients undergoing dCBT compared with those undergoing
single-unit CBT, although the frequency of severe-grade
aGVHD is comparable in the 2 groups [28]. According to
McMillan et al. [28], the increased risk for aGVHD after dCBT
may be the result of a higher dose of T cells in the grafts
when 2 units are used and/or a graft-versus-graft effect,
although the precise mechanism is not clear. In our study,
grade II-IV aGVHD developed in 25% of the patients and
grade III-IV aGVHD occurred in 7%. The fact that the inci-
dence of grade II-IV aGVHD seems to be lower than that
reported by others (eg, 37%-65% incidence of II-IV aGVHD in
dCBT with myeloablative conditioning), and the incidence of
severe aGVHD was comparable [10-15], despite greater HLA
disparities between recipients and donors and between the
2 units in our study. Our lower incidence of aGVHD is likely
related to the different conditioning and GVHD prophylaxis
regimens compared with previous studies [10-15,28]. Theinfused T cell doses in our study may have an inﬂuence on
this ﬁnding, although the infused TNC dose was similar to
that used in previous studies [10,12,13,28]. Ethnic differ-
ences also may contribute to these ﬁndings, as has been
reported by Morishima et al. [29] and Oh et al. [30] Further
studies with larger numbers of patients are needed to
identify the effect of these factors, as well as of HLA
matching, on GVHD.
Our relapse rate at 1 year of 23% is higher than reported in
other studies (eg, relapse incidence of 15% at 5 years by
Brunstein et al. [13], 19% at 5 years by Verneris et al. [12], 19%
by Kang et al. [15], and 20% at 2 years by Kanda et al. [14] for
dCBT after myeloablative conditioning). The relapse rate is
reportedly lower in dCBT recipients compared with single-
unit CBT recipients. Verneris et al. [12] analyzed the
outcomes of CBT for acute leukemia and showed a signiﬁ-
cantly lower relapse rate among patients who received dCBT
in remission compared with patients who underwent single-
unit CBT (16% versus 31%). Rodrigues et al. [11] also reported
a lower risk for relapse in patients with chronic lymphoid
malignancies who underwent dCBT (13% versus 38% at 1
year). Although the precise mechanism is not known, these
data suggest an enhanced graft-versus-leukemia effect in
dCBT. The incidence of grade II-IV aGVHD in the present
study was not higher than that reported in previous studies,
and more patients with advanced risk at the time of dCBT
were included compared with other reports [12-15], which
might reﬂect the somewhat higher relapse rate.
The incidence of TRM (28%) in the present study was
comparable with that reported in other studies of dCBT (29%-
31%) [10-15]. Fifteen of the 29 patients who died did so from
causes not related to relapse. Nine patients died within 100
days after dCBT, and all but 1 death were related to trans-
plantation resultingmainly from graft failure. In addition, the
major cause of death after day 100 was relapse. To improve
survival, strategies to enhance engraftment and reduce
relapse are required.
We demonstrated that survival outcomes and the inci-
dence of engraftment, GVHD, relapse, and TRM seem to be
comparable with that in other reports of dCBT and with our
historical data from single-unit CBT. Interestingly, we also
demonstrated that HLA disparity in the HVG direction has
an impact on determining the grafting unit. Further studies
with larger numbers of patients will be needed to clarify
this and to develop guidelines for selection of units for
dCBT.
In conclusion, we believe that myeloablative dCBT can be
a feasible and effective alternative option for patients with
S. Kai et al. / Biol Blood Marrow Transplant 19 (2013) 812e819818hematologic malignancies who need HSCT but have neither
a suitable related/unrelated donor nor an adequate single-
unit CB graft available. To validate the “double-cord" effect
that is generally assumed to reduce the incidence of relapse,
increase the incidence of aGVHD, and improve survival,
a matched cohort study with a larger number of patients or
a prospective randomized study (if possible), is needed.
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The following transplant centers performed dCBT in this
phase II study and produced follow-up reports: Department
of Hematology, Hyogo College of Medicine; Department of
Hematology, Toranomon Hospital; Department of Hema-
tology and Oncology, Osaka Medical Center for Cancer and
Cardiovascular Disease; Division of Internal Medicine, Sap-
poro Hokuyu Hospital; Division of Hematology and
Oncology, Narita Red Cross Hospital; Department of Hema-
tology, Osaka City University Graduate School of Medicine;
Department of Hematology and Immunology, Tohoku
University; Department of Hematology, Hokkaido Univer-
sity; Department of Hematology, Nippon Medical School
Hospital; Department of Hematology, Tokai University
School of Medicine; Division of Hematology, Osaka Red Cross
Hospital; Division of Pediatrics, Red Cross Nagoya DaiichiHospital; Division of Hematology, Kurashiki Central Hospital;
Division of Transfusion Medicine, Nagaoka Red Cross
Hospital; Division of Hematology, Kanagawa Cancer Center;
Department of Pediatrics, Mie University; Department of
Hematology and Oncology, Osaka Medical Center and
Research Institute of Maternal and Child Health, Division of
Hematology, Hyogo Cancer Center; Division of Internal
Medicine, Hamanomachi Hospital; Department of Bone
Marrow Transplantation, Niigata University Medical and
Dental Hospital; Division of Pediatrics, Kyushu Cancer
Center; Department of Hematology, Kanazawa University;
Division of Hematology, Kumamoto Medical Center;
Department of Hematology and Oncology, Okayama
University; Department of Regenerative Medicine, Institute
of Biomedical Research and Innovation Hospital; Division of
Hematology, Red Cross Nagoya Daiichi Hospital.
